CN105431457A - 单结构域抗体展示 - Google Patents

单结构域抗体展示 Download PDF

Info

Publication number
CN105431457A
CN105431457A CN201480041470.0A CN201480041470A CN105431457A CN 105431457 A CN105431457 A CN 105431457A CN 201480041470 A CN201480041470 A CN 201480041470A CN 105431457 A CN105431457 A CN 105431457A
Authority
CN
China
Prior art keywords
protein
hbcag
nucleic acid
particle
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480041470.0A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·J·罗兰
乔治·罗莫诺索夫
哈德恩·皮雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN105431457A publication Critical patent/CN105431457A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480041470.0A 2013-06-06 2014-06-05 单结构域抗体展示 Pending CN105431457A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831707P 2013-06-06 2013-06-06
US61/831,707 2013-06-06
PCT/GB2014/051739 WO2014195713A1 (en) 2013-06-06 2014-06-05 Single domain antibody display

Publications (1)

Publication Number Publication Date
CN105431457A true CN105431457A (zh) 2016-03-23

Family

ID=51022893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480041470.0A Pending CN105431457A (zh) 2013-06-06 2014-06-05 单结构域抗体展示

Country Status (6)

Country Link
US (1) US20160122420A1 (https=)
EP (1) EP3004173B1 (https=)
JP (1) JP2016528176A (https=)
CN (1) CN105431457A (https=)
CA (1) CA2914555A1 (https=)
WO (1) WO2014195713A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143902A1 (zh) * 2020-01-19 2021-07-22 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
US10544210B2 (en) * 2015-02-03 2020-01-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Rho GTPase conformational single domain antibodies and uses thereof
US11078240B2 (en) 2016-11-11 2021-08-03 Fraunhofer Usa Inc. Covalently fused viral coat proteins for the display of target molecules
WO2021168575A1 (en) * 2020-02-27 2021-09-02 Quadrumix Biotechnology Inc. Polypeptides directed against viral infection and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360556C (zh) * 2000-04-07 2008-01-09 利兹创新有限公司大学 乙型肝炎核心抗原的融合蛋白
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
JP4791730B2 (ja) 2002-09-27 2011-10-12 パウダージェクト リサーチ リミテッド 核酸コーティング粒子
GB0918679D0 (en) * 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
US20130017210A1 (en) * 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360556C (zh) * 2000-04-07 2008-01-09 利兹创新有限公司大学 乙型肝炎核心抗原的融合蛋白
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
江世益等: "《医学有机化学学习指导》", 30 June 1997, 哈尔滨出版社 *
袁勤生主编: "《酶与酶工程》", 31 August 2012, 华东理工大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143902A1 (zh) * 2020-01-19 2021-07-22 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体

Also Published As

Publication number Publication date
EP3004173B1 (en) 2018-05-30
US20160122420A1 (en) 2016-05-05
CA2914555A1 (en) 2014-12-11
EP3004173A1 (en) 2016-04-13
JP2016528176A (ja) 2016-09-15
WO2014195713A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
AU2013305848B2 (en) Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
Dodd et al. Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies: R. Dodd et al.
JP6199036B2 (ja) 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
Klamp et al. Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases
CN114716541B (zh) 抗冠状病毒的全人广谱中和抗体76e1及其应用
CN105431457A (zh) 单结构域抗体展示
WO2014031694A2 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
CN106046155A (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
JP5160545B2 (ja) 特にワクチンに適用される外来分子の提示のための分割コア粒子およびそれらの産生方法
KR20230084478A (ko) 면역원성 코로나 바이러스 융합 단백질 및 관련 방법
WO2025241210A9 (zh) RSV pre-F突变体及其生产方法和用途
WO2018074558A1 (ja) 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン
EP2366709A1 (en) Tumor vaccination involving a humoral immune response against self-proteins
EP3509630A1 (en) Thermostable variants of p. falciparum pfrh5 which can be produced in bacterial cells
US20240156948A1 (en) Vaccine compositions and methods of use thereof
US20140328851A1 (en) Cholesterol Ester Transfer Protein (CETP) Inhibitor Polypeptide Antibodies for Prophylactic and Therapeutic Anti-Atherosclerosis Treatments
JP2011502521A (ja) Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法
JP7806264B2 (ja) パルボウイルスの受容体結合ドメインを含む融合タンパク質、及びこれを含むパルボウイルスに対するワクチン組成物
CN116751266B (zh) 一种亨尼帕病毒保护性抗原及其应用
CN121574211A (zh) 一种新型冠状病毒重组亚单位抗原及其制备方法和在疫苗中的应用
WO2024163327A1 (en) Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024199469A1 (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白
WO2025076013A1 (en) Engineered middle east respiratory syndrome proteins and related methods
EP4630050A1 (en) Broadly neutralizing antibody-templated divalent immunogen vaccines
CN106337038A (zh) 一种通过转肽酶剪切制备疫苗的方法及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160323